CSI Market
Sign In | Register

Fusion Pharmaceuticals Inc (FUSN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access FUSN Annual Cash Flow →
From Fusion Pharmaceuticals Inc through Mar 31 2023, changes in Mar 31 2024's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2024)
3 Months 		(Dec 31 2023) (Sep 30 2023) (Jun 30 2023) (Mar 31 2023)
Operating Activities
Income-33.67
Depreciation & amortization0.36
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation4.52
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.00
Non Cash Lease Expense0.86
Common Shares Issued To Acquire In Process Research And Development-
Increase Decrease In Operating Lease Liability-0.50
Income taxes-0.41
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.01
Increase (Decrease) in Accounts Payable0.45
Increase (Decrease) in Accrued Liabilities3.66
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.61
Other Working Capital-0.65
Other Noncash Income (Expense)-0.32
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.99
Discontinued operations0.00
Net Cash flow from Operating Activities-27.31
Investing Activities
Capital Expenditures-1.33
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments-69.04
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-70.37
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings14.92
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.63
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-62.77
Proceeds From Issance Of Convertible Preferred Stocks Net Of Issuance Cost-
Proceeds From Issuance Of Exchangeable Shares Tranche Right Net Of Issuance Cost-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents62.77
Proceeds From Stock Options And Employee Stock Purchase Plan Exercised-
Proceeds From Issuance Of Common Shares From At Market Offering Net Of Issuance Costs48.47
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities64.01
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-28.64
Total Cash Flow-33.67
4 historic quarters locked

Sign in to unlock the full Fusion Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Fusion Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-24-053958

Figures are derived from filed reports and may be restated. Historical data is subject to revision.